Bone metastases affect prognosis but not effectiveness of third-line targeted therapies in patients with metastatic renal cell carcinoma

INTRODUCTION: Treatment of metastatic renal cell carcinoma (mRCC) has improved with the use of targeted therapies, but bone metastases continue to be negative prognostic factor. METHODS: Patients with mRCC treated with everolimus (EV) or sorafenib (SO) after two previous lines of targeted therapies...

全面介紹

Na minha lista:
書目詳細資料
發表在:Can Urol Assoc J
Main Authors: Iacovelli, Roberto, Santini, Daniele, Rizzo, Mimma, Felici, Alessandra, Santoni, Matteo, Verzoni, Elena, Masini, Cristina, Massari, Francesco, Calvani, Nicola, Mosca, Alessandra, Procopio, Giuseppe
格式: Artigo
語言:Inglês
出版: Canadian Medical Association 2015
主題:
Original Research
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC4537338/
https://ncbi.nlm.nih.gov/pubmed/26316911
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5489/cuaj.2377
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍